Department of Biochemistry

The team studying tumor suppressor protein p53 includes, from left, Jennifer Pietenpol, PhD, and Lindsay Redman-Rivera.

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.

Expression atlas for cell regulators

Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.

Cortez named chair of Department of Biochemistry

David Cortez, PhD, Richard N. Armstrong, PhD, Professor of Innovation in Biochemistry and professor of Biochemistry, has been appointed chair of the Department of Biochemistry.

Madison Adolph, PhD, left, David Cortez, PhD, and Archana Krishnamoorthy are studying fundamental processes involved in DNA replication.

Researchers discover that protein switches functions to regulate DNA replication

Vanderbilt biochemists have discovered what the DNA damage response protein RADX does — and how it does it.

Arrhythmia culprit: supertrafficking ion channel

Charles Sanders, PhD, and colleagues show how a “supertrafficking” mutant potassium channel contributes to heart rhythm abnormalities.

Gene network for leukemia factor

A new method speeds the analysis of factors that control gene expression from days to minutes, allowing researchers to uncover new targets for cancer treatment.

1 2 3 4 5 15